In the midst of a global COVID-19 pandemic, a top priority for many
pharma and biopharma companies is to get a vaccine developed, produced,
and delivered to the public as quickly as possible. Ushering a vaccine
through rigorous testing protocols and regulatory approvals is not an
easy (or quick) effort, but incorporating advanced data analytics could
help accelerate the process. Data analytics has proven effective in
speeding vaccine development both by enabling more efficient Design of
Experiments (DOE) and by creating rapid-scale production rollout
processes. Tomasz Adamusiak, Director of Data Science at Pfizer sits
down with TDS to explain what his company, Pfizer, is doing with the
vaccine as well as what a designed vaccine is.

Tomasz Adamusiak
https://www.linkedin.com/in/adamusiak/

The Data Standard
https://datastandard.io/
https://www.linkedin.com/company/the-data-standard/